Css LLC Biogen Inc. Put Options Transaction History

Css LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2022 Nov 14, 2022	BUY	$194.69 - $268.46 $6.04 Million - $8.32 Million	31,000 New	31,000 $8.28 Million
Q4 2021 Feb 14, 2022	BUY	$223.92 - $287.77 $1.95 Million - $2.5 Million	8,700 Added 378.26%	11,000 $2.64 Million
Q3 2021 Nov 15, 2021	SELL	$282.99 - $369.05 $2.6 Million - $3.4 Million	-9,200 Reduced 80.0%	2,300 $651,000
Q2 2021 Aug 16, 2021	SELL	$259.0 - $414.71 $3.7 Million - $5.93 Million	-14,300 Reduced 55.43%	11,500 $3.98 Million
Q4 2020 Feb 16, 2021	BUY	$236.26 - $355.63 $425,268 - $640,134	1,800 Added 7.5%	25,800 $6.32 Million
Q3 2020 Nov 16, 2020	SELL	$264.77 - $305.71 $2.65 Million - $3.06 Million	-10,000 Reduced 29.41%	24,000 $6.81 Million
Q2 2020 Aug 14, 2020	BUY	$258.66 - $342.55 $2.59 Million - $3.43 Million	10,000 Added 41.67%	34,000 $9.1 Million
Q1 2020 May 15, 2020	BUY	$268.85 - $341.04 $5.78 Million - $7.33 Million	21,500 Added 860.0%	24,000 $7.59 Million
Q4 2019 Feb 14, 2020	BUY	$220.06 - $304.07 $550,150 - $760,175	2,500 New	2,500 $742,000

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Css LLC, based on Form 13F filings with the SEC.

Stay updated on Css LLC with notifications on news.